VALBY, Denmark & LA JOLLA, Calif.--(BUSINESS WIRE)--H. Lundbeck A/S (Lundbeck) and Longboard Pharmaceuticals, Inc (NASDAQ: LBPH) (Longboard) today announced an agreement for Lundbeck to acquire Longboard. Under the terms of the agreement, Lundbeck will commence a tender offer for all outstanding shares of Longboard common stock, whereby Longboard shareholders will be offered a payment of USD 60.00 per share in cash.

丹麦瓦尔比（VALBY）和加利福尼亚州拉霍亚（LA JOLLA）——H.Lundbeck A/S（Lundbeck）和Longboard Pharmaceuticals，Inc（NASDAQ:LBPH）（Longboard）今天宣布了Lundbeck收购Longboard的协议。根据协议条款，伦贝克将开始对所有已发行的长板普通股进行要约收购，从而向长板股东提供每股60.00美元的现金支付。

The transaction is valued at approximately USD 2.6 billion equity value and USD 2.5 billion (approximately DKK 17 billion) net of cash, on a fully diluted basis..

在完全摊薄的基础上，该交易的股权价值约为26亿美元，现金净额约为25亿美元（约170亿丹麦克朗）。

The board of directors of both companies have unanimously approved the transaction. The transaction is expected to close in the fourth quarter of 2024, subject to the tender of at least a majority of the total number of Longboard outstanding voting shares, receipt of required regulatory clearances, and other customary conditions..

两家公司的董事会一致批准了这项交易。该交易预计将于2024年第四季度完成，但须满足至少大部分已发行有投票权的长板股票的投标、获得所需的监管许可以及其他习惯条件。

Longboard is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Its lead asset, bexicaserin, has shown encouraging anti-seizure reduction to date in preclinical and clinical studies, with its next-generation superagonist mechanism specifically targeting 5-HT2C receptors, which support bexicaserin’s potential to offer a highly differentiated and best-in-class profile.

Longboard是一家临床阶段的生物制药公司，专注于开发针对神经系统疾病的新型转化药物。其主要资产贝西卡西林迄今为止在临床前和临床研究中显示出令人鼓舞的抗癫痫发作减少，其下一代超性腺激素机制专门针对5-HT2C受体，这支持贝西卡西林提供高度分化和同类最佳概况的潜力。

Bexicaserin is now being evaluated in a global phase III clinical program (the DEEp Program)..

贝昔卡塞林目前正在全球III期临床计划（DEEp计划）中接受评估。

“This transformative transaction will become a cornerstone in Lundbeck’s neuro-rare franchise, with a potential to drive growth into the next decade. Bexicaserin addresses a critical unmet need for patients suffering from rare and severe epilepsies, for which there are very few good treatment options available.

“这项具有变革性的交易将成为伦贝克神经罕见病特许经营权的基石，有可能推动未来十年的增长。贝西卡西林解决了罕见和严重癫痫患者的关键需求，而对于这些患者来说，几乎没有好的治疗选择。

With this acquisition, we continue to execute on our Focused Innovator strategy, transforming the lives of patients suffering from severe brain disorders,” said Charl van Zyl, President and CEO of Lundbeck..

通过此次收购，我们将继续实施专注的创新战略，改变患有严重脑部疾病的患者的生活，”伦贝克公司总裁兼首席执行官查尔·范泽尔（CharlvanZyl）表示。

“Longboard was founded to transform the lives of people living with devastating neurological conditions. I am incredibly proud of what our team has achieved; delivering groundbreaking data with a differentiated and inclusive clinical approach to address the needs of a wide range of DEEs and obtaining Breakthrough Therapy designation,” stated Kevin R.

Kevin R.表示：“Longboard的成立是为了改变患有毁灭性神经疾病的人们的生活。我为我们的团队取得的成就感到无比骄傲；通过差异化和包容性的临床方法提供开创性的数据，以满足各种DEE的需求，并获得突破性的治疗指定。”。

Lind, President and Chief Executive Officer of Longboard. “I would like to thank the entire DEE community, in particular bexicaserin’s study participants and their caregivers as well as the advocacy groups, investigators, sites and coordinators for their support and partnership. Lundbeck’s remarkable capabilities will accelerate our vision to provide increased equity and access for underserved DEE patients with significant unmet medical needs.”.

林德（Lind），Longboard总裁兼首席执行官。“我要感谢整个DEE社区，特别是bexicaserin的研究参与者及其护理人员，以及倡导团体、调查人员、网站和协调员的支持和合作。伦贝克的卓越能力将加速我们的愿景，为服务不足且医疗需求严重未得到满足的DEE患者提供更多的公平和机会。”

Strategic benefits

战略利益

The acquisition of Longboard marks a strategic milestone for Lundbeck, enhancing and complementing our Focused Innovator strategy and advancing our goal of building a neuro-rare disease franchise.

收购Longboard标志着Lundbeck的一个战略里程碑，加强和补充了我们专注的创新战略，推进了我们建立神经罕见病特许经营权的目标。

Through the acquisition of Longboard, Lundbeck gains access to bexicaserin, a novel 5-HT2C agonist in development for the treatment of seizures associated with DEEs, including Dravet syndrome, Lennox-Gastaut syndrome, and other rare epilepsies. This aligns with Lundbeck’s expertise in delivering innovative treatments and re-establishes our scientific and commercial leadership in rare epilepsies.

通过收购Longboard，Lundbeck获得了bexicaserin，这是一种正在开发的新型5-HT2C激动剂，用于治疗与DEEs相关的癫痫发作，包括Dravet综合征，Lennox-Gastaut综合征和其他罕见癫痫。这与伦贝克在提供创新治疗方面的专业知识相吻合，并重新确立了我们在罕见癫痫病方面的科学和商业领导地位。

Bexicaserin has entered a global phase III trial (DEEp SEA Study) evaluating bexicaserin for the treatment of seizures associated with Dravet syndrome in participants two years of age and older. The DEEp SEA Study is part of a broader DEEp Program (DEEp SEA, DEEp OCEAN and DEEp OLE) which is planned to take place across ~80 sites globally and include ~480 participants with a range of DEEs.

贝西卡西林已进入一项全球III期试验（深海研究），评估贝西卡西林治疗两岁及以上参与者与Dravet综合征相关的癫痫发作。深海研究是更广泛的深海项目（深海、深海和深海OLE）的一部分，该项目计划在全球约80个地点进行，包括约480名参与者和一系列DEE。

Bexicaserin has received Breakthrough Therapy Designation (BTD) from the U.S. FDA and is set to become a cornerstone of Lundbeck’s new neuro-rare disease franchise. Recent nine-month open-label data further supports the de-risked nature of its 5-HT2C mode-of-action, highlighting its superior target product profile..

Bexicaserin已获得美国FDA的突破性治疗指定（BTD），并将成为Lundbeck新的神经罕见病特许经营的基石。最近9个月的开放标签数据进一步支持了其5-HT2C行动模式的去风险性质，突出了其优越的目标产品概况。

The bexicaserin asset complements Lundbeck’s mid- to late-stage pipeline and diversifies revenue growth following the expected launch in the fourth quarter of 2028 and with a global peak sales potential estimated by Lundbeck between USD 1.5 - 2 billion.

bexicaserin资产补充了Lundbeck的中后期管道，并在2028年第四季度预计推出后实现了收入增长的多样化，Lundbeck估计全球销售潜力峰值在15-20亿美元之间。

Terms, closing conditions and financing

条款、交割条件和融资

Under the terms of the agreement, Lundbeck will commence a tender offer for all outstanding shares of Longboard common stock, whereby Longboard shareholders will be offered a payment for USD 60 per share in cash. The cash consideration represents a 77% premium to the 30-day volume-weighted average price (“VWAP”) of shares of Longboard common stock as of September 30, 2024..

根据协议条款，伦贝克将开始对所有已发行的长板普通股进行要约收购，从而向长板股东提供每股60美元的现金支付。现金对价比截至2024年9月30日的长板普通股30天成交量加权平均价格（“VWAP”）溢价77%。

If the tender offer is consummated, Lundbeck will acquire any shares of Longboard common stock not tendered into the tender offer through a merger for the same per share consideration as will be payable in the tender offer. The merger will occur as soon as practicable after the closing of the tender offer..

如果要约收购完成，伦贝克将以与要约收购中应付的每股对价相同的价格，通过合并收购未被要约收购的任何长板普通股。合并将在要约收购结束后尽快进行。

Lundbeck expects to fund the acquisition through existing cash resources and its existing bank financing facility. Following closing of the transaction, Lundbeck will focus on de-leveraging and leverage is expected to be in Lundbeck’s target range of <2.5x NIBD/EBITDA within 18-24 months.

伦贝克预计将通过现有现金资源及其现有的银行融资机制为收购提供资金。交易结束后，伦贝克将专注于去杠杆化，预计在18-24个月内，杠杆率将达到伦贝克的目标范围，即<2.5倍NIBD/EBITDA。

The terms and conditions of the tender offer will be described in the tender offer documents, which will be filed with the U.S. Securities and Exchange Commission.

投标报价的条款和条件将在投标报价文件中描述，投标报价文件将提交给美国证券交易委员会。

We expect to recognize integration costs in the amount of approximately USD 80 million (approximately DKK 550 million), which predominantly will impact 2024 and will be adjusted for in Adjusted EBITDA. Lundbeck’s financial guidance for 2024 is confirmed.

我们预计确认整合成本约为8000万美元（约5.5亿丹麦克朗），主要影响2024年，并将在调整后的息税折旧摊销前利润中进行调整。伦贝克（Lundbeck）2024年的财务指导得到确认。

Advisors

顾问

For Lundbeck, PJT Partners LP is acting as exclusive financial advisor and Baker McKenzie is acting as legal advisor in this transaction. For Longboard, Evercore and Centerview Partners LLC are acting as financial advisors and Cooley LLP is acting as legal advisor.

对于Lundbeck，PJT Partners LP在此次交易中担任独家财务顾问，Baker McKenzie担任法律顾问。对于Longboard，Evercore和Centerview Partners LLC担任财务顾问，Cooley LLP担任法律顾问。

Conference Call

电话会议

Today at 13:30 pm (CET), Lundbeck will be hosting a conference call for the financial community. To participate in the conference call please follow the instructions below

今天下午13:30（CET），伦贝克将为金融界举办电话会议。要参加电话会议，请按照以下说明进行

Webcast streaming link: Conference call

网络广播流链接：电话会议

Teleconference registration link: Teleconference registration

电话会议注册链接：电话会议注册

About the DEEp SEA Study

关于深海研究

The DEEp SEA Study (LP352-302) is a global phase III double-blind, placebo-controlled clinical trial to evaluate the efficacy of bexicaserin in Dravet syndrome as assessed by countable motor seizures in ~160 participants between the ages of two and 65 years old. An important secondary objective is to evaluate the safety and tolerability of bexicaserin.

深海研究（LP352-302）是一项全球III期双盲安慰剂对照临床试验，旨在评估贝西卡塞林在Dravet综合征中的疗效，该试验通过约160名2至65岁参与者的可计数运动性癫痫发作进行评估。一个重要的次要目标是评估贝西卡西林的安全性和耐受性。

Following a 5-week screening period and baseline evaluations, study participants initiate dose titration over a 3-week period and subsequently continue on the highest tolerated dose throughout the maintenance period of 12-weeks. Following the maintenance period, eligible participants will be given the opportunity to enroll in the 52-week DEEp Open-Label Extension (DEEp OLE Study LP352-303).

经过5周的筛查期和基线评估后，研究参与者在3周内开始剂量滴定，随后在12周的维持期内继续使用最高耐受剂量。维护期结束后，符合条件的参与者将有机会参加为期52周的深度开放标签扩展（深度OLE研究LP352-303）。

The phase III DEEp SEA Study is part of the broader DEEp Program which will take place across ~80 sites globally and include ~480 participants with a range of Developmental and Epileptic Encephalopathies (DEEs)..

第三阶段深海研究是更广泛的深海项目的一部分，该项目将在全球约80个地点进行，包括约480名患有一系列发育性和癫痫性脑病（DEE）的参与者。

About Developmental and Epileptic Encephalopathies (DEEs)

关于发育性和癫痫性脑病（DEEs）

Epilepsy is the third leading contributor to the global burden of neurological disorders and affects 65 million people worldwide. DEEs are a group of severe early-childhood onset epilepsies characterized by refractory seizures and developmental delay and/or regression. These diseases are often progressive and commonly show resistance to treatment.

癫痫病是造成全球神经系统疾病负担的第三大原因，影响着全世界6500万人。DEEs是一组严重的儿童早期发作性癫痫，其特征是难治性癫痫发作，发育迟缓和/或消退。这些疾病通常是进行性的，通常表现出对治疗的抵抗力。

DEEs encompass a diverse range of over 25 syndromes, of which only four currently have FDA-approved therapies with partial treatment responses. Consequently, there is a remaining significant unmet need to find therapies that efficiently act across the DEE spectra. Some common epilepsy syndromes that are DEEs include:.

DEEs涵盖了25多种综合征，其中目前只有4种具有FDA批准的部分治疗反应的疗法。因此，仍然需要找到在DEE光谱中有效起作用的疗法。DEEs的一些常见癫痫综合征包括：。

Dravet syndrome

Dravet综合征

Lennox-Gastaut syndrome

Lennox-Gastaut综合征

Tuberous sclerosis complex

结节性硬化症

CDKL5 deficiency disorder

CDKL5缺乏症

Early infantile epileptic encephalopathy, including Ohtahara syndrome and early myoclonic encephalopathy

早期婴儿癫痫性脑病，包括大田原综合征和早期肌阵挛性脑病

Infantile epileptic spasms syndrome, including West syndrome

婴儿癫痫痉挛综合征，包括韦斯特综合征

Febrile infection-related epilepsy syndrome

发热感染相关性癫痫综合征

Epilepsy of infancy with migrating focal seizures

婴儿期癫痫伴迁移性局灶性癫痫发作

Epilepsy with myoclonic-atonic seizures, otherwise known as myoclonic-atonic epilepsy (MAE) or Doose syndrome.

伴有肌阵挛性无张力癫痫发作的癫痫，也称为肌阵挛性无张力癫痫（MAE）或Doose综合征。

Landau-Kleffner syndrome

Landau-Kleffner综合征

Developmental and epileptic encephalopathy with spike and wave activation in sleep (DEE-SWAS)

睡眠中棘波激活的发育性和癫痫性脑病（DEE-SWAS）

While these syndromes are individually considered an orphan disease, altogether we estimate approximately 220,000 patients are affected by DEE syndromes in the U.S.

虽然这些综合征被单独视为孤儿疾病，但我们估计在美国大约有220000名患者受到DEE综合征的影响。

About Longboard Pharmaceuticals

关于Longboard Pharmaceuticals

Longboard is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor super-agonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, is being evaluated in a global phase III clinical program (the DEEp Program).

Longboard是一家临床阶段的生物制药公司，专注于开发针对神经系统疾病的新型转化药物。Longboard的小分子产品候选产品基于20多年的GPCR研究。Bexicaserin（LP352）是一种口服，中枢作用的5-羟色胺2C（5-HT2C）受体超级激动剂，对5-HT2B和5-HT2A受体亚型没有观察到影响，正在全球III期临床计划中进行评估（深度计划）。

Bexicaserin has Rare Pediatric Disease and Orphan Drug designations, and the FDA has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age and older..

贝西卡塞林具有罕见的儿科疾病和孤儿药物名称，FDA已授予贝西卡塞林突破性治疗名称，用于治疗两岁及以上患者与发育性和癫痫性脑病（DEEs）相关的癫痫发作。

Bexicaserin is an investigational compound that is not approved for marketing by the FDA or any other regulatory authority.

Bexicaserin是一种研究性化合物，未经FDA或任何其他监管机构批准上市。

About H. Lundbeck A/S

关于H.Lundbeck A/S

Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Lundbeck是一家专注于大脑健康的生物制药公司。凭借70多年的神经科学经验，我们致力于改善神经和精神疾病患者的生活。

Brain disorders affect a large part of the world’s population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.

脑部疾病影响着全球大部分人口，其后果波及整个社会。随着人们对大脑生物学认识的迅速提高，我们有责任通过好奇地探索新的治疗机会来促进大脑健康。

As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology..

我们开发了针对很少或没有可用治疗方法的人群的变革性药物，从我们在精神病学和神经病学领域的强大遗产中扩展到神经专科和神经罕见。

We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.

我们致力于消除耻辱感，并采取行动改善卫生公平。我们努力为股东创造长期价值，为患者及其家人和整个社会做出积极贡献。

Lundbeck has approximately 5,500 employees in more than 50 countries and our products are available in more than 80 countries.

伦贝克在50多个国家拥有约5500名员工，我们的产品在80多个国家销售。